#ban

1 article tagged #ban.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

Editorial photograph illustrating the FDA compounded semaglutide enforcement crackdown
NewsCost & InsuranceJune 19, 202613 min read

Compounded Semaglutide Ban (2026): FDA Crackdown Explained + 4 Legal Switch Options

Updated June 29, 2026: FDA issued 30 warning letters to telehealth companies June 15 for illegally marketing compounded GLP-1s. 503B permanent exclusion comment period extended to July 30, 2026 (from June 29 via FR 2026-12937). FDA proposed April 30 to permanently remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. 503A enforcement began April 22, 2025. 503B enforcement May 22, 2025. 3-4 million patients affected. Legal alternatives: compounded tirzepatide ($149-299/mo, medical-necessity only), Wegovy $349/mo via NovoCare, or Foundayo from $149/mo self-pay.

Featured Partners

Four affiliate partners we feature, we may earn a commission.

TrimRx

7.8/10
$149/mo·Compounded

Gala

7.2/10
$149/mo·Brand & Compounded

Embody

7.3/10
$149/mo·Compounded

SkinnyRx

7.3/10
$199/mo·Compounded

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.